525
Participants
Start Date
November 1, 2016
Primary Completion Date
January 31, 2021
Study Completion Date
January 31, 2021
Sitagliptin - DPP4i
DPP4 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
Canagliflozin - SGLT2i
SGLT2 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
Pioglitazone - TZD
Thiazolidinedione 30mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
Exeter Clinical Research Facility, Exeter
Royal Devon and Exeter NHS Foundation Trust
OTHER
University of Exeter
OTHER
NHS Tayside
OTHER_GOV
University of Dundee
OTHER
University of Glasgow
OTHER
Newcastle University
OTHER
King's College London
OTHER